Apixaban 5 Mg Tablet

Description

1.Eliquis is a factor Xa inhibitor anticoagulant indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation . .DOSAGE AND ADMINISTRATION.1] The recommended dose is 5 mg orally twice daily.(2.1)2] In patients with at least 2 of the following characteristics: age 80 years, body weight 60 kg, or serum creatinine 1.5 mg/dL, the recommended dose is 2.5 mg orally twice daily. (2.2)DOSAGE FORMS AND STRENGTHS.- Tablets: 2.5 mg and 5 mg (3).WARNINGS AND PRECAUTIONS.1.ELIQUIS can cause serious, potentially fatal bleeding. Promptly evaluate signs and symptoms of blood loss. (5.2).2. Prosthetic heart valves: ELIQUIS use not recommended. .ADVERSE REACTIONS.1] Most common adverse reactions (>1%) are related to bleeding.2] (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch——————————–DRUG INTERACTIONS—————————– 1. Strong dual inhibitors of CYP3A4 and P-gp increase blood levels of apixaban: Reduce ELIQUIS dose to 2.5 mg or avoid concomitant use. (2.2, 7.1, 12.3)2.Simultaneous use of strong inducers of CYP3A4 and P-gp reduces blood levels of apixaban: Avoid concomitant use. (7.2, 12.3).